Altre lingue InnoCan Pharma Corporation Deutsche Boerse AG

Azioni

IP4

CA45783P1027

Mercato chiuso - Deutsche Boerse AG Altri mercati azionari 13:55:25 07/06/2024			Variaz. 5gg	Var. 1 gen.
0,1945 ^EUR	+6,28%		+0,78%	-0,36%

27/05	InnoCan Pharma Corporation riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
27/05	Innocan Pharma riporta i risultati del primo trimestre 2024 con una crescita del fatturato di oltre 4 volte a 6,8 milioni di dollari	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

InnoCan Pharma Corporation: Innocan Pharma meldet Ergebnisse für das erste Quartal 2024: Mehr als vierfacher Umsatzzuwachs auf 6,8 Mio. Dollar	28/05
InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	27/05
Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million	27/05
Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million	27/05
Refile: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	21/05
InnoCan Pharma Brief: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	21/05
InnoCan Pharma Corporation: FDA hat Innocan Pharma einen Besprechungstermin für LPT-CBD zur Behandlung von chronischen Schmerzen gewährt	21/05
FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	21/05
InnoCan Pharma Corporation: Innocan Pharma meldet Durchbruch in einem vorklinischen Versuch: Durch die Injektion mit Liposom-CBD wird die Mobilität einer Eselin mit amputiertem Bein wiederhergestellt	10/05
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey	09/05
Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey	09/05
InnoCan Pharma Corporation: Innocan Pharma leitet FDA-Zulassungsverfahren für Liposomen-Injektionstherapie gegen chronische Schmerzen ein	23/04
InnoCan Pharma Corporation Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain	22/04
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain	22/04
InnoCan Pharma Corporation: Innocan Pharma gibt die Gesamtergebnisse des Jahres 2023 bekannt Umsätze um das 6-Fache auf 13,7 Mio. $ gestiegen	02/04
InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M	01/04
InnoCan Pharma Corporation: Innocan Pharma ebnet Weg zu Chemie, Herstellung und Kontrollen (CMC) von LPT-CBD, den wichtigsten Meilensteinen für die FDA-Zulassung	26/03
Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University	25/03
InnoCan Pharma "Paves Its Way" to LPT-CBD Chemistry, Manufacturing and Controls (CMC), "Key Milestones" for FDA Approval	25/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue InnoCan Pharma Corporation Deutsche Boerse AG

Azioni

IP4

CA45783P1027

Altre lingue

Filtri